// App-Quantinova.ai

5014 : Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D).

Researchers

Presenter

  • Robert B. Montgomery

Principal Investigators

  • Thian San Kheoh

  • Arturo Molina

  • Jinhui Li

  • Joaquim Bellmunt

  • Charles J. Ryan

  • Namphuong Tran

  • Yohann Loriot

  • Eleni Efstathiou

  • Howard I. Scher

  • Johann Sebastian De Bono

Medical Centers

  • University Hospital del Mar-IMIM, Barcelona, Spain

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • University of Washington, Seattle, WA

  • Deptartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center/Deptartment of Clinical Therapeutics, The University of Athens Greece, Houston, TX

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Janssen Research & Development, LLC, Raritan, NJ

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Janssen Research & Development, Los Angeles, CA

  • Institut Gustave-Roussy, Villejuif, France

Locations

  • United States

  • Spain

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Docetaxel

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • NCT00638690

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved